Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 13.74B P/E 41.42 EPS this Y -18.90% Ern Qtrly Grth -
Income 1.13B Forward P/E 7.90 EPS next Y 9.00% 50D Avg Chg -3.00%
Sales 2.35B PEG 2.66 EPS past 5Y 41.67% 200D Avg Chg -16.00%
Dividend 2.00% Price/Book 2.31 EPS next 5Y 3.20% 52W High Chg -31.00%
Recommedations 1.90 Quick Ratio 7.87 Shares Outstanding 446.69M 52W Low Chg 5.00%
Insider Own 3.87% ROA 5.62% Shares Float 384.12M Beta 0.42
Inst Own 71.92% ROE 17.34% Shares Shorted/Prior 10.28M/11.21M Price 30.65
Gross Margin 76.19% Profit Margin 48.20% Avg. Volume 2,432,067 Target Price 45.50
Oper. Margin 102.82% Earnings Date May 7 Volume 1,837,290 Change -0.81%
About Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Royalty Pharma plc News
02/18/24 Analysts Have Made A Financial Statement On Royalty Pharma plc's (NASDAQ:RPRX) Yearly Report
02/17/24 Royalty Pharma Full Year 2023 Earnings: EPS: US$2.54 (vs US$0.098 in FY 2022)
02/16/24 Royalty Pharma PLC (RPRX): A Strategic SWOT Insight
02/15/24 Royalty Pharma PLC (RPRX) Earnings Report: A Detailed Analysis
02/15/24 Royalty Pharma Reports Q4 and Full Year 2023 Results
01/30/24 Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
01/22/24 Royalty Pharma (NASDAQ:RPRX) Is Paying Out A Larger Dividend Than Last Year
01/19/24 Royalty Pharma Announces Dividend Increase
01/08/24 Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
11/27/23 Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
08:03 AM Royalty Pharma plc (NASDAQ:RPRX) is a favorite amongst institutional investors who own 69%
11/13/23 Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
11/13/23 Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
11/09/23 The Royalty Pharma PLC (RPRX) Company: A Short SWOT Analysis
11/08/23 Royalty Pharma Reports Third Quarter 2023 Results
10/19/23 Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi
10/16/23 Royalty Pharma Declares Fourth Quarter 2023 Dividend
10/11/23 Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023
09/21/23 Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
09/12/23 Are Royalty Pharma plc's (NASDAQ:RPRX) Mixed Financials Driving The Negative Sentiment?
RPRX Chatroom

User Image Doozio Posted - 4 days ago

$RPRX still ain’t got da huckleberries. Bahht da obvious appears obvious. Obviously. Chop chop huckleberries. 🧠⏰

User Image regard2WSB Posted - 4 days ago

$RPRX better get in on the action, Golden Cross is about to form

User Image TipRanks Posted - 5 days ago

TipRanks’‘Perfect 10’ List: These 2 Biotech Stocks Look Compelling at Current Levels https://www.tipranks.com/news/article/tipranksperfect-10-list-these-2-biotech-stocks-look-compelling-at-current-levels $CLDX $RPRX

User Image Doozio Posted - 6 days ago

$RPRX wen a 🧠👀 becomes chop chop huckleberries 🧠⏰. N it’s still so early.

User Image Jasooon Posted - 1 week ago

$RPRX, BofA giving a PT of $40 and reiterating buy.

User Image StockBraker Posted - 1 week ago

$RPRX Outlook is moderate for 2024. Debt is still too high. Would like to see continuing share repurchase.

User Image YungBull100 Posted - 1 week ago

$RPRX moon you slootz

User Image epsguid Posted - 1 week ago

$RPRX reported earnings of $1.15, consensus was $1.03 via @eWhispers #epsbeat http://eps.sh/d/rprx

User Image Stock_Titan Posted - 1 week ago

$RPRX Royalty Pharma Reports Q4 and Full Year 2023 Results https://www.stocktitan.net/news/RPRX/royalty-pharma-reports-q4-and-full-year-2023-tt724h3o6u5d.html

User Image UncleStock Posted - 2 weeks ago

$RPRX $VTRS $PFE $ZTS suggested for $DRG US ARCA Pharmaceutical - value screen: https://zpr.io/tykPs

User Image regard2WSB Posted - 2 weeks ago

$RPRX higher highs/higher lows.. wen moon

User Image ViktorSinclair Posted - 2 weeks ago

$RPRX Just keep shorting this. It is the stock that keeps on giving. Poor management that is constantly selling will lead to its collapse. Just look at the chart since IPO and look at what every insider has done since IPO. This company when public solely for the mechanism for them to unload shares, that's it. I was long and saw the light.

User Image TalkMarkets Posted - 2 weeks ago

How Risky Is Royalty Pharma’s Dividend? $RPRX https://talkmarkets.com/content/stocks--equities/how-risky-is-royalty-pharmas-dividend?post=430968

User Image JaydenBest Posted - 2 weeks ago

$RPRX $TPIC $STEM Analyst price target for today\\ https://live-alerts-stock-trades.topmarketwatch.vip

User Image Cfl41m Posted - 2 weeks ago

$RPRX Whats up with the green and volume? I cant find any news?

User Image GSP Posted - 2 weeks ago

$GRRR $IMNM $KOD $NRBO $RPRX

User Image GSP Posted - 2 weeks ago

Day traders look for 'in play' stocks to trade 'between the bells'. $RPRX makes my list.

User Image GSP Posted - 2 weeks ago

Trading Watch List Video for February 7th (con't): $RPRX $IMNM $KOD $GRRR $NRBO Watch here: https://greatstockpix.com/february-7th-day-trading-watch-list/

User Image Jasooon Posted - 2 weeks ago

$RPRX will benefit greatly from $MOR being acquired by $NVS. They had a stake in MorphoSys and will now benefit from Novartis' R&D and commercial expertise for pipeline development and eventual commercialization. https://www.royaltypharma.com/news/royalty-pharma-announces-2025-billion-strategic-funding/ https://www.bloomberg.com/news/articles/2024-02-05/morphosys-surges-on-report-novartis-is-in-talks-to-buy-drugmaker

User Image Pdq3 Posted - 2 weeks ago

$RPRX How much they making off their MOR investment?

User Image sa_trader Posted - 3 weeks ago

$RPRX New add, 50MA support is good entry point. Also 50MA curving upwards

User Image Cfl41m Posted - 3 weeks ago

$RPRX Dividend increase is always a good sign!

User Image Jasooon Posted - 01/30/24

$RPRX $BMY https://www.fiercepharma.com/special-reports/top-10-most-anticipated-drug-launches-2024

User Image ForestFoxes Posted - 01/28/24

@jimmy18000 @G37X @BaneyBoy35 🦄$ANVS 🤝 $RPRX💰 = Best 🌈 Path 🛣️ https://www.royaltypharma.com

User Image ViktorSinclair Posted - 4 weeks ago

$RPRX Look at the price action since IPO. They (insiders) have been dumping this as fast they can since the 3 month lockup.. BTW who ever heard of a 3 month lock up? They went public just so they can unload this shit. It was massive pump and dump scheme.

User Image JonG12345 Posted - 1 month ago

$RPRX 5 months without reaching the 30$, what a shame

User Image ChartMill Posted - 1 month ago

Pocket pivot signals in $RPRX, $VUSB, $DBD, $GGAL and $FDEC, while they also have the support from large players according to the effective volume indicator. https://www.chartmill.com/stock/stock-screener?sid=31&f=smlev20v_b_lev,smlev20v_r,p_pg10,pp_1,v1_50b200,cu_a_sm50v,der5_a_0.03,s_ppt,exch_us&v=3&timeframe=DAILY&type=CANDLES&o1=17&op1=10%252C2,16711680&i1=49&ia1=on&cl=F&months=0.05&o2=3&op2=50,255&width=720&o3=3&op3=10,65280&utm_source=large_effective_volume_+_pocket_pivot_today&utm_medium=stocktwits&utm_campaign=screen

User Image YungBull100 Posted - 1 month ago

$RPRX added

User Image pepe7 Posted - 1 month ago

$RPRX

User Image Jasooon Posted - 1 month ago

$RPRX, wadduppppppp https://x.com/paras_biotech/status/1749229906217591178?s=46&t=7vIazpOiaR63N_ccf3b54A

Analyst Ratings
JP Morgan Overweight Feb 20, 24
Goldman Sachs Buy Feb 20, 24
Morgan Stanley Overweight Nov 9, 23
Morgan Stanley Overweight Oct 11, 23
Morgan Stanley Overweight Aug 9, 23
Morgan Stanley Overweight Jul 11, 23
Morgan Stanley Overweight May 10, 23
Morgan Stanley Overweight Apr 10, 23
Tigress Financial Buy Apr 6, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
RIGGS RORY B Director Director Jan 02 Sell 27.95 470,000 13,136,500 20,099 01/04/24
Avara Management Ltd 10% Owner 10% Owner Dec 27 Sell 28.11 251,592 7,072,251 2,543,323 12/29/23
Coyne Terrance P. EVP & CFO EVP & CFO Aug 09 Sell 30.73 75,000 2,304,750 790,000 08/11/23
Coyne Terrance P. EVP & CFO EVP & CFO Jul 12 Sell 31 75,000 2,325,000 865,000 07/14/23
Lloyd George W. EVP, Investments & C.. EVP, Investments & CLO Jun 02 Sell 33.63 192,221 6,464,392 30,000 06/06/23
Legorreta Pablo G. CEO, Chairman of the.. CEO, Chairman of the Board May 24 Buy 32.2496 150,000 4,837,440 380,000 05/24/23
RIGGS RORY B Director Director May 22 Sell 32.82 1,750,000 57,435,000 6,762 05/22/23
RIGGS RORY B Director Director Mar 29 Sell 36.6 139,950 5,122,170 1,456,762 03/30/23
Lloyd George W. EVP, Investments & C.. EVP, Investments & CLO Mar 28 Sell 37.04 112,779 4,177,334 212,221 03/30/23
Lloyd George W. EVP, Investments & C.. EVP, Investments & CLO Feb 23 Sell 37.2663 25,000 931,658 325,000 02/27/23
Urist Marshall EVP, Research & Inve.. EVP, Research & Investments Feb 22 Sell 37.2965 23,333 870,239 46,667 02/24/23
RIGGS RORY B Director Director Dec 09 Sell 42.02 60,000 2,521,200 96,712 12/13/22
Coyne Terrance P. EVP & CFO EVP & CFO Nov 02 Sell 43.0629 5,500 236,846 964,500 11/04/22
Giuliani Mario Germano Director Director Sep 28 Sell 41.05 32,593 1,337,943 8,077,140 09/30/22
Giuliani Mario Germano Director Director Sep 22 Sell 41.1681 211,380 8,702,113 8,109,733 09/26/22
GG 1978 SICAF SIF S.A. - GG St... 10% Owner 10% Owner Sep 20 Sell 41.0201 267,815 10,985,798 21,426,170 09/22/22
Giuliani Mario Germano Director Director Sep 16 Sell 41.61 387,171 16,110,185 22,657,815 09/20/22
GG 1978 SICAF SIF S.A. - GG St... 10% Owner 10% Owner Sep 16 Sell 41.61 387,171 16,110,185 21,693,985 09/20/22
RIGGS RORY B Director Director Sep 14 Sell 42.31 100,000 4,231,000 276,712 09/15/22
Giuliani Mario Germano Director Director Sep 07 Sell 42.7 499,500 21,328,650 8,577,140 09/09/22
GG 1978 SICAF SIF S.A. - GG St... 10% Owner 10% Owner Sep 07 Sell 42.7 498,006 21,264,856 22,426,170 09/09/22
GG 1978 SICAF SIF S.A. - GG St... 10% Owner 10% Owner Aug 25 Sell 44 1,994 87,736 22,924,176 08/29/22
Giuliani Mario Germano Director Director Aug 25 Sell 44 500 22,000 9,076,640 08/29/22
RIGGS RORY B Director Director Aug 09 Sell 43.7294 45,000 1,967,823 376,712 08/11/22
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Aug 09 Sell 43.92 20,854 915,908 201,114 08/11/22
Coyne Terrance P. EVP & CFO EVP & CFO Aug 01 Sell 43.1909 30,000 1,295,727 970,000 08/03/22
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Jul 28 Sell 43.9676 4,046 177,893 221,968 08/01/22
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Jul 25 Sell 43.28 75,100 3,250,328 226,014 07/27/22
Urist Marshall EVP, Research & Inve.. EVP, Research & Investments Jul 25 Sell 43.12 23,334 1,006,162 07/27/22
RIGGS RORY B Director Director Jun 29 Sell 42.1746 30,000 1,265,238 421,712 06/29/22
Urist Marshall EVP, Research & Inve.. EVP, Research & Investments Jun 24 Sell 43.1875 23,333 1,007,694 23,334 06/24/22
Reddoch James F. EVP & Chief Scientif.. EVP & Chief Scientific Officer Jun 08 Sell 41.559 100,000 4,155,900 920,800 06/10/22
Reddoch James F. EVP & Chief Scientif.. EVP & Chief Scientific Officer May 27 Sell 41.0801 75,000 3,081,008 1,020,800 05/31/22
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC May 26 Sell 40.49 100,000 4,049,000 430,000 05/31/22
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC May 23 Sell 40.2677 100,000 4,026,770 530,000 05/25/22
Urist Marshall EVP, Research & Inve.. EVP, Research & Investments May 16 Sell 39.8507 23,333 929,836 46,667 05/16/22
RIGGS RORY B Director Director Mar 29 Sell 38.5887 60,000 2,315,322 601,712 03/30/22
RIGGS RORY B Director Director Mar 17 Sell 39.33 169,089 6,650,270 03/21/22
Fernandez Henry A Director Director Feb 24 Buy 37.4884 32,500 1,218,373 58,200 02/25/22
RIGGS RORY B Director Director Dec 28 Sell 40.16 184,448 7,407,432 592,748 12/30/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Nov 16 Sell 42.51 250,000 10,627,500 630,000 11/18/21
RIGGS RORY B Director Director Nov 16 Sell 42.28 214,389 9,064,367 1,115,645 11/18/21
RIGGS RORY B Director Director Jun 29 Sell 42.17 1,314,912 55,449,839 3,451,258 06/29/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Jun 14 Sell 46.47 70,000 3,252,900 240,000 06/14/21
Urist Marshall EVP & Co-Head of R&I EVP & Co-Head of R&I Jun 08 Sell 46.08 33,134 1,526,815 06/08/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Jun 04 Sell 42.11 62,500 2,631,875 1,050,000 06/04/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Apr 16 Sell 42.13 69,822 2,941,601 200,000 04/16/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Apr 14 Sell 42.32 449 19,002 255,898 04/14/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Mar 04 Sell 47.37 125,000 5,921,250 300,000 03/04/21
Reddoch James F. EVP, Research & Inve.. EVP, Research & Investments Mar 04 Sell 47.37 100,000 4,737,000 300,000 03/04/21